KLTO (Klotho Neurosciences) Accounts Receivable : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Klotho Neurosciences Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Klotho Neurosciences's accounts receivables for the quarter that ended in Sep. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Klotho Neurosciences's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $-0.04.

Klotho Neurosciences Accounts Receivable Historical Data

The historical data trend for Klotho Neurosciences's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Klotho Neurosciences Accounts Receivable Chart

Klotho Neurosciences Annual Data

Trend

Dec21

Dec22

Accounts Receivable

Klotho Neurosciences Quarterly Data
	Dec21	Jun22	Dec22	Jun23	Sep23	Mar24	Jun24	Sep24
Accounts Receivable	Get a 7-Day Free Trial			-	-	-	-	-

Klotho Neurosciences Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Klotho Neurosciences Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Klotho Neurosciences's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Klotho Neurosciences's accounts receivable are only considered to be worth 75% of book value:

Klotho Neurosciences's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(0.051	+	0.75 * 0	+	0.5 * 0	-	1.004
-	0	-	0)	/	21.2635
=	-0.04

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Klotho Neurosciences Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Klotho Neurosciences's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Klotho Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Klotho Neurosciences Inc (NAS:KLTO) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

13576 Walnut Street, 12th Floor, Omaha, NE, USA, 68144

Website

https://www.klothoneuro.com

Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.